These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34672772)

  • 1. Dapagliflozin Reduces Urinary Albumin Excretion by Downregulating the Expression of cAMP, MAPK, and cGMP-PKG Signaling Pathways Associated Genes.
    Chen G; Wang H; Zhang W; Zhou J
    Genet Test Mol Biomarkers; 2021 Oct; 25(10):627-637. PubMed ID: 34672772
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy.
    Bai Z; Xie T; Liu T; Chen Z; Yu L; Zhang C; Luo J; Chen L; Zhao X; Xiao Y
    Front Endocrinol (Lausanne); 2022; 13():967822. PubMed ID: 36213291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
    Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
    Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
    Petrykiv SI; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2017 Oct; 19(10):1363-1370. PubMed ID: 28295959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
    Dekkers CCJ; Petrykiv S; Laverman GD; Cherney DZ; Gansevoort RT; Heerspink HJL
    Diabetes Obes Metab; 2018 Aug; 20(8):1988-1993. PubMed ID: 29573529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort.
    Jensen M; Eickhoff MK; Persson F; Rossing P; Thiel S; Hansen SWK; Palarasah Y; Svenningsen P; Jensen BL
    Immunobiology; 2024 May; 229(3):152797. PubMed ID: 38518448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.
    Mulder S; Heerspink HJL; Darshi M; Kim JJ; Laverman GD; Sharma K; Pena MJ
    Diabetes Obes Metab; 2019 Nov; 21(11):2422-2428. PubMed ID: 31264758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
    Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level.
    Cho J; Doo SW; Song N; Lee M; Lee H; Kim H; Jeon JS; Noh H; Kwon SH
    Clin Pharmacol Ther; 2024 Jun; 115(6):1441-1449. PubMed ID: 38451017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    van Bommel EJM; Muskiet MHA; van Baar MJB; Tonneijck L; Smits MM; Emanuel AL; Bozovic A; Danser AHJ; Geurts F; Hoorn EJ; Touw DJ; Larsen EL; Poulsen HE; Kramer MHH; Nieuwdorp M; Joles JA; van Raalte DH
    Kidney Int; 2020 Jan; 97(1):202-212. PubMed ID: 31791665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.
    de Jong MA; Petrykiv SI; Laverman GD; van Herwaarden AE; de Zeeuw D; Bakker SJL; Heerspink HJL; de Borst MH
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):66-73. PubMed ID: 30559106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
    Yoshihara F; Imazu M; Hamasaki T; Anzai T; Yasuda S; Ito S; Yamamoto H; Hashimura K; Yasumura Y; Mori K; Watanabe M; Asakura M; Kitakaze M;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):183-190. PubMed ID: 29589153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
    Heerspink HJL; Sjöström CD; Inzucchi SE; Hallow MK; Cain VA; Rossing P; Stefansson BV; Sartipy P
    Diabetes Obes Metab; 2019 Mar; 21(3):720-725. PubMed ID: 30414240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.